IGF-1 LR3: The Messenger Growth Hormone Actually Sends
Growth hormone does surprisingly little directly. Most of what it is credited with is carried out by IGF-1 — and LR3 is a modified version built to evade the system that normally restrains it.
What Is IGF-1 LR3?
IGF-1 — insulin-like growth factor 1 — is the molecule that carries out most of what growth hormone is credited with. Growth hormone travels to the liver, the liver produces IGF-1, and IGF-1 does much of the actual work at the tissues.
The relationship, in plain language: growth hormone is less a workman than a manager who sends memos. It arrives at the liver, issues an instruction, and IGF-1 is the worker despatched to carry it out. This is why the growth hormone literature so often measures IGF-1 levels rather than growth hormone itself — growth hormone comes in brief pulses that are hard to catch, while IGF-1 is steadier and reflects what the system actually did.
LR3 is a modified version. The Long refers to a 13-amino-acid extension, and the R3 to a substitution at position three. Both changes serve one purpose: evading the binding proteins that normally hold IGF-1 in check.
Why the Modification Matters
Natural IGF-1 does not circulate freely. It travels bound to carrier proteins that keep it inactive until released, which is how the body regulates a signal that instructs cells to grow and divide.
The restraint system, in plain language: a powerful instruction needs a safety catch. IGF-1 tells cells to grow, and unrestrained growth signalling is exactly what you do not want circulating freely — so the body keeps most of it bound up and releases it deliberately. LR3 is modified specifically so those carrier proteins cannot hold it, which greatly extends how long it stays active. That is precisely why it is a research tool rather than something with a straightforward path to approved use: removing a safety catch is useful in a laboratory and a serious question anywhere else.
Research using LR3 concerns cell proliferation and differentiation, muscle satellite cell behaviour, and growth signalling pathways. It holds no regulatory approval anywhere.
Frequently Asked Questions
Compiled by the Southern Pacific Labs research team. Last updated July 2026.
Published References
- Tomas FM, Knowles SE, Owens PC, et al. “Effects of full-length and truncated insulin-like growth factor-I on nitrogen balance and muscle protein metabolism in nitrogen-restricted rats.” The Journal of endocrinology, 1991. PubMed
- Le Roith D, Bondy C, Yakar S, et al. “The somatomedin hypothesis: 2001.” Endocrine reviews, 2001. PubMed
- Clemmons DR. “Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer.” Nature reviews. Drug discovery, 2007. PubMed
- Sigalos JT, Pastuszak AW. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews, 2018. PubMed
Related Research Guides
More in Growth Hormone & Endocrine
The category that produces the signal IGF-1 carries out.
Read guide →GHRH AnalogueA compound whose research measures IGF-1 as its main readout.
Read guide →Essential ReadingWhy binding proteins and clearance shape how long a compound acts.
Read guide →